HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC
Publication
, Conference
Xu, L; Saha, A; Parrott, R; O'Neil, S; Kurtzberg, J; Filiano, AJ
Published in: CYTOTHERAPY
2022
Duke Scholars
Published In
CYTOTHERAPY
EISSN
1477-2566
ISSN
1465-3249
Publication Date
2022
Volume
24
Issue
5
Start / End Page
S26 / S26
Related Subject Headings
- Immunology
- 3206 Medical biotechnology
- 3204 Immunology
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Xu, L., Saha, A., Parrott, R., O’Neil, S., Kurtzberg, J., & Filiano, A. J. (2022). HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC. In CYTOTHERAPY (Vol. 24, pp. S26–S26).
Xu, L., A. Saha, R. Parrott, S. O’Neil, J. Kurtzberg, and A. J. Filiano. “HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC.” In CYTOTHERAPY, 24:S26–S26, 2022.
Xu L, Saha A, Parrott R, O’Neil S, Kurtzberg J, Filiano AJ. HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC. In: CYTOTHERAPY. 2022. p. S26–S26.
Xu, L., et al. “HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC.” CYTOTHERAPY, vol. 24, no. 5, 2022, pp. S26–S26.
Xu L, Saha A, Parrott R, O’Neil S, Kurtzberg J, Filiano AJ. HUMAN UMBILICAL CORD BLOOD DERIVED CELL THERAPY PRODUCT, DUOC-01, PROMOTES REMYELINATION BY DRIVING THE DIFFERENTIATION OF OPC. CYTOTHERAPY. 2022. p. S26–S26.
Published In
CYTOTHERAPY
EISSN
1477-2566
ISSN
1465-3249
Publication Date
2022
Volume
24
Issue
5
Start / End Page
S26 / S26
Related Subject Headings
- Immunology
- 3206 Medical biotechnology
- 3204 Immunology
- 1103 Clinical Sciences